Clinical & Experimental Metastasis,
Journal Year:
2023,
Volume and Issue:
40(3), P. 217 - 226
Published: May 23, 2023
Brain
metastases
(BM)
in
patients
with
thyroid
cancer
(TC)
are
rare
an
incidence
of
1%
for
papillary
and
follicular,
3%
medullary
up
to
10%
anaplastic
TC
(PTC,
FTC,
MTC
ATC).
Little
is
known
about
the
characteristics
management
BM
from
TC.
Thus,
we
retrospectively
analyzed
histologically
verified
radiologically
identified
Vienna
Metastasis
Registry.
A
total
20/6074
included
database
since
1986
had
13/20
were
female.
Ten
8
PTC,
one
ATC.
The
median
age
at
diagnosis
was
68
years.
All
but
symptomatic
a
singular
BM.
Synchronous
primary
found
6
patients,
while
time
13
years
PTC
(range
1.9-24),
4
FTC
2.1-41)
22
patient.
overall
survival
months
1.8-57),
26
3.9-188),
12
3
ATC
In
conclusion,
development
exceedingly
most
common
presentation
single
lesion.
While
generally
constitute
poor
prognostic
factor,
individual
experience
long-term
following
local
therapy.
Biomedicines,
Journal Year:
2023,
Volume and Issue:
11(4), P. 1217 - 1217
Published: April 19, 2023
Follicular
thyroid
carcinoma
(FTC)
is
the
second
most
common
cancer
of
gland,
accounting
for
up
to
20%
all
primary
malignant
tumors
in
iodine-replete
areas.
The
diagnostic
work-up,
staging,
risk
stratification,
management,
and
follow-up
strategies
patients
who
have
FTC
are
modeled
after
those
papillary
(PTC),
even
though
more
aggressive.
has
a
greater
propensity
haematogenous
metastasis
than
PTC.
Furthermore,
phenotypically
genotypically
heterogeneous
disease.
diagnosis
identification
markers
an
aggressive
depend
on
expertise
thoroughness
pathologists
during
histopathological
analysis.
An
untreated
or
metastatic
likely
de-differentiate
become
poorly
differentiated
undifferentiated
resistant
standard
treatment.
While
lobectomy
adequate
treatment
selected
low-risk
FTC,
it
not
advisable
whose
tumor
larger
4
cm
diameter
extensive
extra-thyroidal
extension.
Lobectomy
also
that
mutations.
Although
prognosis
over
80%
PTC
good,
nearly
behave
aggressively.
introduction
radiomics,
pathomics,
genomics,
transcriptomics,
metabolomics,
liquid
biopsy
led
improvements
understanding
tumorigenesis,
progression,
response,
prognostication
cancer.
article
reviews
challenges
encountered
FTC.
How
application
multi-omics
can
strengthen
decision-making
management
follicular
discussed.
LabMed discovery.,
Journal Year:
2024,
Volume and Issue:
1(1), P. 100011 - 100011
Published: Aug. 27, 2024
Precise
tumor
diagnosis
and
treatment
require
the
support
of
abundant
molecular
information.
However,
conventional
diagnostic
technologies
gradually
fail
to
satisfy
demands
clinical
therapy
due
limited
detection
performance.
Benefiting
from
highly
specific
target
sequence
recognition
efficient
cis/trans
cleavage
activity,
CRISPR/Cas
system
has
been
widely
employed
construct
novel
strategies,
hailed
as
"next-generation
technology".
This
review
focuses
on
recent
advances
in
CRISPR
systems
for
variant
gene,
protein,
liquid
biopsy
biomarker,
outlines
strategies
situ
detection.
In
addition,
we
explore
general
principles
development
trends
construction
emphasize
revolutionary
impact
that
it
brought
field
diagnostics.
Journal of Histochemistry & Cytochemistry,
Journal Year:
2022,
Volume and Issue:
70(10), P. 707 - 716
Published: Oct. 1, 2022
Thymosin
beta-4
(TMSB4X)
was
recently
identified
as
a
differentially
expressed
gene
between
malignant
and
non-malignant
thyroid
cells
via
single-cell
RNA
sequencing.
In
the
present
study,
we
aimed
to
study
immunostaining
pattern
of
TMSB4X
in
benign
neoplasms.
Immunohistochemical
analysis
revealed
that
normal
tissue
or
disorders
exhibited
undetectable
immunoreactivity
against
except
for
positive
staining
inflammatory
infiltrates
stromal
associated
with
autoimmune
disease.
By
contrast,
overexpression
observed
variety
malignancies,
including
papillary,
follicular,
poorly
differentiated,
undifferentiated
cancer.
Among
141
patients
differentiated
cancer,
higher
expression
papillary
tumor
type,
extrathyroidal
extension,
lymph
node
metastasis,
BRAF
V600E
mutation.
The
results
were
consistent
those
from
public
transcriptomic
datasets.
summary,
aberrantly
increased
various
types
correlated
advanced
disease
characteristics.
may
be
novel
downstream
effector
Clinical & Experimental Metastasis,
Journal Year:
2023,
Volume and Issue:
40(3), P. 217 - 226
Published: May 23, 2023
Brain
metastases
(BM)
in
patients
with
thyroid
cancer
(TC)
are
rare
an
incidence
of
1%
for
papillary
and
follicular,
3%
medullary
up
to
10%
anaplastic
TC
(PTC,
FTC,
MTC
ATC).
Little
is
known
about
the
characteristics
management
BM
from
TC.
Thus,
we
retrospectively
analyzed
histologically
verified
radiologically
identified
Vienna
Metastasis
Registry.
A
total
20/6074
included
database
since
1986
had
13/20
were
female.
Ten
8
PTC,
one
ATC.
The
median
age
at
diagnosis
was
68
years.
All
but
symptomatic
a
singular
BM.
Synchronous
primary
found
6
patients,
while
time
13
years
PTC
(range
1.9-24),
4
FTC
2.1-41)
22
patient.
overall
survival
months
1.8-57),
26
3.9-188),
12
3
ATC
In
conclusion,
development
exceedingly
most
common
presentation
single
lesion.
While
generally
constitute
poor
prognostic
factor,
individual
experience
long-term
following
local
therapy.
